WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 528909

CAS#: 947620-48-6

Description: RVT-501, also known as E-6005 and lotamilast, is a phosphodiesterase 4 (PDE-4) inhibitor potentially for the treatment of atopic dermatitis.

Price and Availability


USD 150
USD 750
USD 3450

USD 250
USD 1150
USD 4850

USD 450
USD 1950
USD 7950

RVT-501 (E-6005), purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 528909
Name: RVT-501
CAS#: 947620-48-6
Chemical Formula: C26H24N4O5
Exact Mass: 472.1747
Molecular Weight: 472.5
Elemental Analysis: C, 66.09; H, 5.12; N, 11.86; O, 16.93

Synonym: E-6005; E6005; E6005; RVT-501; RVT501; RVT 501; lotamilast;

IUPAC/Chemical Name: methyl 4-((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)carbamoyl)benzoate


InChi Code: InChI=1S/C26H24N4O5/c1-27-26-29-20-14-22(34-3)21(33-2)13-19(20)23(30-26)17-6-5-7-18(12-17)28-24(31)15-8-10-16(11-9-15)25(32)35-4/h5-14H,1-4H3,(H,28,31)(H,27,29,30)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Nemoto O, Hayashi N, Kitahara Y, Furue M, Hojo S, Nomoto M, Shima S; Japanese E6005 Study Investigators.. Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial. J Dermatol. 2016 Aug;43(8):881-7. doi: 10.1111/1346-8138.13231. PubMed PMID: 26703371.

2: Mano Y, Ishii T, Hotta K, Kusano K. Validation of a UPLC-MS/MS method for the simultaneous determination of E6005, a phosphodiesterase 4 inhibitor, and its metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Aug 15;998-999:31-9. doi: 10.1016/j.jchromb.2015.06.023. PubMed PMID: 26149248.

3: Furue M, Kitahara Y, Akama H, Hojo S, Hayashi N, Nakagawa H; JAPANESE E6005 Study Investigators.. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol. 2014 Jul;41(7):577-85. doi: 10.1111/1346-8138.12534. PubMed PMID: 24942594.

4: Ohba F, Nomoto M, Hojo S, Akama H. Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis. J Dermatolog Treat. 2016;27(3):241-6. doi: 10.3109/09546634.2015.1093587. PubMed PMID: 26581111.

5: Ohba F, Matsuki S, Imayama S, Matsuguma K, Hojo S, Nomoto M, Akama H. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study. J Dermatolog Treat. 2016 Oct;27(5):467-72. doi: 10.3109/09546634.2016.1157257. PubMed PMID: 27080209.

6: Andoh T, Kuraishi Y. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP. J Dermatol Sci. 2014 Dec;76(3):206-13. doi: 10.1016/j.jdermsci.2014.10.005. PubMed PMID: 25458869.

7: Wakita H, Ohkuro M, Ishii N, Hishinuma I, Shirato M. A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves. Exp Dermatol. 2015 Mar;24(3):215-6. doi: 10.1111/exd.12606. PubMed PMID: 25431172.

8: Kubota S, Watanabe M, Shirato M, Okuno T, Higashimoto I, Machida K, Yokomizo T, Inoue H. An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice. Eur J Pharmacol. 2015 Dec 5;768:41-8. doi: 10.1016/j.ejphar.2015.10.013. PubMed PMID: 26455478.

9: Ishii N, Shirato M, Wakita H, Miyazaki K, Takase Y, Asano O, Kusano K, Yamamoto E, Inoue C, Hishinuma I. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12. doi: 10.1124/jpet.113.205542. PubMed PMID: 23674603.

10: Andoh T, Yoshida T, Kuraishi Y. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis. Exp Dermatol. 2014 May;23(5):359-61. doi: 10.1111/exd.12377. PubMed PMID: 24645735.

11: Ishii N, Wakita H, Shirato M. Effect of the phosphodiesterase 4 inhibitor E6005 on nerve growth factor elevation in irritated skin of NC/Nga mice. J Dermatol Sci. 2014 Dec;76(3):263-4. doi: 10.1016/j.jdermsci.2014.09.010. PubMed PMID: 25455141.

12: Leaños-Miranda A, Méndez-Aguilar F, Ramírez-Valenzuela KL, Serrano-Rodríguez M, Berumen-Lechuga G, Molina-Pérez CJ, Isordia-Salas I, Campos-Galicia I. Circulating angiogenic factors are related to the severity of gestational hypertension and preeclampsia, and their adverse outcomes. Medicine (Baltimore). 2017 Jan;96(4):e6005. doi: 10.1097/MD.0000000000006005. PubMed PMID: 28121958; PubMed Central PMCID: PMC5287982.

13: Mano Y, Kita K, Kusano K. Hematocrit-independent recovery is a key for bioanalysis using volumetric absorptive microsampling devices, Mitra™. Bioanalysis. 2015;7(15):1821-9. doi: 10.4155/bio.15.111. PubMed PMID: 26295984.

14: Nakamuta JS, Danoviz ME, Marques FL, dos Santos L, Becker C, Gonçalves GA, Vassallo PF, Schettert IT, Tucci PJ, Krieger JE. Cell therapy attenuates cardiac dysfunction post myocardial infarction: effect of timing, routes of injection and a fibrin scaffold. PLoS One. 2009 Jun 23;4(6):e6005. doi: 10.1371/journal.pone.0006005. PubMed PMID: 19547700; PubMed Central PMCID: PMC2695782.

15: Kuo I I, Fischer B, Vlahov D. Consideration of a North American heroin-assisted clinical trial for the treatment of opiate-dependent individuals. Int J Drug Policy. 2000 Sep 1;11(5):357-370. PubMed PMID: 10967518.